Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)

Summary

This is a pharmacogenomic prospective , four-arms, parallel groups, active comparator controlled study in essential hypertensive patients never treated before. Each patient will be genotyped for SNPs (single nucleotide polymorphism) in preliminary genetic profiles and will be treated according to their genetic profile with Peri (Perindopril) 4 mg or HCTZ ( hydrochlorothiazide) 12.5 mg.

Timeline

Start

2016-03

Primary completion

2018-03

Completion

2018-11

Drugs

Indications